7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide
| Title | Journal |
|---|---|
| Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. | Toxicology letters 20180701 |
| Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. | The Lancet. Oncology 20180701 |
| A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. | Clinical cancer research : an official journal of the American Association for Cancer Research 20161201 |
| Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. | The New England journal of medicine 20161103 |
| Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20131115 |
| A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. | Cancer biology & therapy 20130701 |
| The requirement for cyclin D function in tumor maintenance. | Cancer cell 20121016 |
| Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. | Cancer cell 20121016 |
| Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. | Cell cycle (Georgetown, Tex.) 20120715 |
| Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. | Biochimica et biophysica acta 20110801 |
| A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. | Cancer cell 20100713 |
| The landscape of somatic copy-number alteration across human cancers. | Nature 20100218 |
| Requirement for CDK4 kinase function in breast cancer. | Cancer cell 20060101 |